Last reviewed · How we verify
Sancuso - Part 1
Sancuso - Part 1 is a Small molecule drug developed by Kyowa Kirin, Inc.. It is currently in Phase 1 development. Also known as: Granisetron Transdermal Patch.
Sancuso is a medication used to treat various conditions, including solid tumors, papillomavirus infections, cervical intraepithelial neoplasia, carcinoma in situ, and vulvar neoplasms. It is a CYP1A2, CYP2C19, and CYP3A substrate, and its effects on these enzymes and the QT interval have been studied in a phase I clinical trial.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Sancuso - Part 1 |
|---|---|
| Also known as | Granisetron Transdermal Patch |
| Sponsor | Kyowa Kirin, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- Staccato® Granisetron Single Dose PK (PHASE1)
- Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches. (PHASE1)
- Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sancuso - Part 1 CI brief — competitive landscape report
- Sancuso - Part 1 updates RSS · CI watch RSS
- Kyowa Kirin, Inc. portfolio CI
Frequently asked questions about Sancuso - Part 1
What is Sancuso - Part 1?
Who makes Sancuso - Part 1?
Is Sancuso - Part 1 also known as anything else?
What development phase is Sancuso - Part 1 in?
Related
- Manufacturer: Kyowa Kirin, Inc. — full pipeline
- Also known as: Granisetron Transdermal Patch
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing